Search results
Results From The WOW.Com Content Network
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients ...
Aerie Pharmaceuticals is a spin-out from Duke research by co-founder Dr. David Epstein on retinal diseases, glaucoma and dry eye syndrome Durham pharma company acquired by international eye-care ...
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
For premium support please call: 800-290-4726 more ways to reach us
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Pages for logged out editors learn more
Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering BEDMINSTER, N.J & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Aerie ...
Alcon offices in Johns Creek, Georgia. Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund ...